Chao Y - Search Results

1

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT; Taiwan Cooperative Oncology Group. Chen JS, et al. Among authors: chao y. Ann Oncol. 2015 May;26(5):943-949. doi: 10.1093/annonc/mdv035. Epub 2015 Jan 28. Ann Oncol. 2015. PMID: 25632066 Free article. Clinical Trial.

2

An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer.

Chao Y, Li CP, Chao TY, Su WC, Hsieh RK, Wu MF, Yeh KH, Kao WY, Chen LT, Cheng AL. Chao Y, et al. Among authors: chao ty. Br J Cancer. 2006 Jul 17;95(2):159-63. doi: 10.1038/sj.bjc.6603225. Epub 2006 Jun 27. Br J Cancer. 2006. PMID: 16804524 Free PMC article. Clinical Trial.

3

Continuous infusion cisplatin and etoposide chemotherapy for cancer of unknown primary site (CUPS) in Taiwan, a region with a high prevalence of endemic viral infections.

Liu JM, Chen YM, Chao Y, Liu SM, Tiu CM, Wu HW, Chiou TC, Hsieh RK, Chen LT, Whang-Peng J. Liu JM, et al. Among authors: chao y. Jpn J Clin Oncol. 1998 Jul;28(7):431-5. doi: 10.1093/jjco/28.7.431. Jpn J Clin Oncol. 1998. PMID: 9739784

4

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.

Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, Hsieh RK, Cheng AL. Chao Y, et al. Among authors: chao ty. Br J Cancer. 2004 Aug 2;91(3):453-8. doi: 10.1038/sj.bjc.6601985. Br J Cancer. 2004. PMID: 15226770 Free PMC article. Clinical Trial.

5

A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.

Li CP, Chen JS, Chen LT, Yen CJ, Lee KD, Su WP, Lin PC, Lu CH, Tsai HJ, Chao Y. Li CP, et al. Among authors: chao y. Br J Cancer. 2010 Oct 26;103(9):1343-8. doi: 10.1038/sj.bjc.6605928. Epub 2010 Oct 5. Br J Cancer. 2010. PMID: 20924378 Free PMC article. Clinical Trial.

6

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT. Abou-Alfa GK, et al. Among authors: chao y. Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101. Ann Oncol. 2018. PMID: 29659672 Free article. Clinical Trial.

7

alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.

Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, Chen SC, Chuang TR, Chin YH, Whang-Peng J. Chen LT, et al. Among authors: chao y. Aliment Pharmacol Ther. 2005 Aug 1;22(3):217-26. doi: 10.1111/j.1365-2036.2005.02547.x. Aliment Pharmacol Ther. 2005. PMID: 16091059 Free article.

8

Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.

Chao Y, Teng HC, Hung HC, King KL, Li CP, Chi KH, Yen SH, Chang FY. Chao Y, et al. Jpn J Clin Oncol. 2000 Mar;30(3):122-5. doi: 10.1093/jjco/hyd038. Jpn J Clin Oncol. 2000. PMID: 10798538 Clinical Trial.

9

Evaluation of GL331 in combination with paclitaxel: GL331's interference with paclitaxel-induced cell cycle perturbation and apoptosis.

Huang TS, Shu CH, Chao Y, Chen LT. Huang TS, et al. Among authors: chao y. Anticancer Drugs. 2001 Mar;12(3):259-66. doi: 10.1097/00001813-200103000-00011. Anticancer Drugs. 2001. PMID: 11290873

10

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.

Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. Roy AC, et al. Among authors: chao y. Ann Oncol. 2013 Jun;24(6):1567-73. doi: 10.1093/annonc/mdt002. Epub 2013 Feb 13. Ann Oncol. 2013. PMID: 23406728 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,344 results

Search Page